Proton Pump Inhibitor Selection in Dyspepsia

Initial Treatment

• The American College of Gastroenterology recommends that any commercially available PPI can be used as first-line therapy for dyspepsia, as absolute differences in efficacy for symptom control are small and all PPIs are functionally equivalent when dosed appropriately 1
• Start with standard-dose PPI once daily, taken 30-60 minutes before a meal, for 4-8 weeks as first-line therapy for dyspepsia without alarm symptoms 1, 2
• PPIs are superior to H2-receptor antagonists, which are in turn superior to placebo, for treating dyspepsia 1, 2

Symptom-Based Approach

• For ulcer-like dyspepsia, full-dose PPI therapy is the first choice, with symptom response confirming the acid-related nature 3, 2
• For dysmotility-like dyspepsia, consider adding a prokinetic agent to PPI therapy, though PPI monotherapy remains reasonable 3, 2

Treatment Escalation

• If symptoms persist after 4-8 weeks of once-daily PPI, increase to twice-daily PPI dosing for an additional 4-8 weeks 1, 2
• If symptoms persist despite twice-daily PPI for 8 weeks, proceed to endoscopy to evaluate for structural disease or alternative diagnoses 1, 2

H. Pylori Considerations

• Test for H. pylori using urea breath test or stool antigen test in patients with dyspepsia; eradicate if positive 4, 2
• H. pylori eradication is estimated to be responsible for only 5% of dyspepsia improvement in the community, but identifies most peptic ulcer disease cases 4

Long-Term Management

• If symptoms resolve with initial therapy, taper PPI to the lowest effective dose 1
• Consider on-demand therapy with the successful agent for maintenance, though data are limited in functional dyspepsia 3
• For patients requiring long-term PPI therapy, objective reflux testing should be considered to confirm the diagnosis 1

Proton Pump Inhibitors for Dyspepsia Management

Initial Management and Treatment

• The American Gastroenterological Association recommends testing for H. pylori first in all patients with dyspepsia, and receiving eradication therapy if positive, as part of the initial management steps 5
• The American Gastroenterological Association suggests empirical PPI therapy for H. pylori-negative patients, as part of the initial management steps 5
• The use of the lowest effective dose of PPI is recommended, as there is no dose-response relationship demonstrated, according to the American Gastroenterological Association 5

Long-Term Management Considerations

• The American Gastroenterological Association recommends documenting appropriate indications for PPI use and considering de-prescribing in the absence of an ongoing appropriate indication 6
• The American Gastroenterological Association suggests that most patients with dyspepsia have nonerosive disease and should be considered for a trial of de-prescribing after symptom control is achieved 6
• The American Gastroenterological Association recommends avoiding unnecessary long-term PPI use in patients without complicated GERD, and considering de-prescribing once symptoms are controlled 6

Guideline Recommendations for Proton‑Pump Inhibitor Use in Functional Dyspepsia

First‑Line Therapy

• The British Society of Gastroenterology strongly recommends proton‑pump inhibitors as first‑line empirical therapy for functional dyspepsia, demonstrating superiority over placebo, H₂‑receptor antagonists, and antacid combinations. Strong recommendation, high‑quality evidence 7
• A strong recommendation based on high‑quality evidence (British Society of Gastroenterology, 2022) states that PPIs are efficacious for functional dyspepsia with a number‑needed‑to‑treat of 11. Strong recommendation, high‑quality evidence 7

Helicobacter pylori Management

• Testing all patients for H. pylori (urea breath test or stool antigen) before or concurrent with PPI initiation, and eradicating infection when positive, is strongly recommended. Strong recommendation, high‑quality evidence 7

Treatment Escalation

• If symptoms persist after an initial 4–8‑week standard‑dose PPI course, escalation to twice‑daily PPI dosing for an additional 4–8 weeks is advised before proceeding to endoscopy. Strong recommendation, high‑quality evidence 7
• Tricyclic antidepressants (e.g., amitriptyline, starting 10 mg once daily and titrating to 30–50 mg) are recommended as second‑line therapy when symptoms remain despite optimal PPI therapy. Strong recommendation, moderate‑quality evidence 7

Safety and Tolerability

• All PPIs are well‑tolerated, with adverse‑event profiles comparable to placebo. Strong recommendation, high‑quality evidence 7

Adjunctive Measures

• Regular aerobic exercise is advised for all patients with functional dyspepsia. Strong recommendation, high‑quality evidence 7
• Current evidence is insufficient to support specific dietary interventions, including low‑FODMAP diets, for functional dyspepsia. Insufficient evidence 7